P1135: SUBCUTANEOUS EPCORITAMAB IN COMBINATION WITH RITXUIMAB + LENALIDOMIDE IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PHASE 1/2 TRIAL UPDATE
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000847408.61609.bd |
| _version_ | 1797285965887176704 |
|---|---|
| author | D. Belada S. Leppä B. E. Wahlin M. Nijland J. H. Christensen S. de Vos H. Holte K. M. Linton A. Abbas L. Wang M. Dinh B. Elliott L. Falchi |
| author_facet | D. Belada S. Leppä B. E. Wahlin M. Nijland J. H. Christensen S. de Vos H. Holte K. M. Linton A. Abbas L. Wang M. Dinh B. Elliott L. Falchi |
| author_sort | D. Belada |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:10:44Z |
| format | Article |
| id | doaj.art-daf66731ffa945d7b73d1d281d451070 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:10:44Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-daf66731ffa945d7b73d1d281d4510702024-03-02T07:47:21ZengWileyHemaSphere2572-92412022-06-0161025102610.1097/01.HS9.0000847408.61609.bd202206003-01025P1135: SUBCUTANEOUS EPCORITAMAB IN COMBINATION WITH RITXUIMAB + LENALIDOMIDE IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PHASE 1/2 TRIAL UPDATED. Belada0S. Leppä1B. E. Wahlin2M. Nijland3J. H. Christensen4S. de Vos5H. Holte6K. M. Linton7A. Abbas8L. Wang9M. Dinh10B. Elliott11L. Falchi121 4th Department of Internal Medicine – Hematology, University Hospital and Faculty of Medicine, Hradec Králové, Czechia2 Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland3 Karolinska Institutet, Stockholm, Sweden4 University Medical Center Groningen and University of Groningen, Groningen, Netherlands5 Odense University Hospital, Odense, Denmark6 Ronald Reagan University of California Los Angeles Medical Center, Los Angeles, United States of America7 Oslo University Hospital and KG Jebsen Center for B-cell Malignancies, Oslo, Norway8 The Christie NHS Foundation Trust and Manchester Cancer Research Centre, Manchester, United Kingdom9 Genmab, Princeton9 Genmab, Princeton10 AbbVie, North Chicago9 Genmab, Princeton11 Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, United States of Americahttp://journals.lww.com/10.1097/01.HS9.0000847408.61609.bd |
| spellingShingle | D. Belada S. Leppä B. E. Wahlin M. Nijland J. H. Christensen S. de Vos H. Holte K. M. Linton A. Abbas L. Wang M. Dinh B. Elliott L. Falchi P1135: SUBCUTANEOUS EPCORITAMAB IN COMBINATION WITH RITXUIMAB + LENALIDOMIDE IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PHASE 1/2 TRIAL UPDATE HemaSphere |
| title | P1135: SUBCUTANEOUS EPCORITAMAB IN COMBINATION WITH RITXUIMAB + LENALIDOMIDE IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PHASE 1/2 TRIAL UPDATE |
| title_full | P1135: SUBCUTANEOUS EPCORITAMAB IN COMBINATION WITH RITXUIMAB + LENALIDOMIDE IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PHASE 1/2 TRIAL UPDATE |
| title_fullStr | P1135: SUBCUTANEOUS EPCORITAMAB IN COMBINATION WITH RITXUIMAB + LENALIDOMIDE IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PHASE 1/2 TRIAL UPDATE |
| title_full_unstemmed | P1135: SUBCUTANEOUS EPCORITAMAB IN COMBINATION WITH RITXUIMAB + LENALIDOMIDE IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PHASE 1/2 TRIAL UPDATE |
| title_short | P1135: SUBCUTANEOUS EPCORITAMAB IN COMBINATION WITH RITXUIMAB + LENALIDOMIDE IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PHASE 1/2 TRIAL UPDATE |
| title_sort | p1135 subcutaneous epcoritamab in combination with ritxuimab lenalidomide in relapsed or refractory follicular lymphoma phase 1 2 trial update |
| url | http://journals.lww.com/10.1097/01.HS9.0000847408.61609.bd |
| work_keys_str_mv | AT dbelada p1135subcutaneousepcoritamabincombinationwithritxuimablenalidomideinrelapsedorrefractoryfollicularlymphomaphase12trialupdate AT sleppa p1135subcutaneousepcoritamabincombinationwithritxuimablenalidomideinrelapsedorrefractoryfollicularlymphomaphase12trialupdate AT bewahlin p1135subcutaneousepcoritamabincombinationwithritxuimablenalidomideinrelapsedorrefractoryfollicularlymphomaphase12trialupdate AT mnijland p1135subcutaneousepcoritamabincombinationwithritxuimablenalidomideinrelapsedorrefractoryfollicularlymphomaphase12trialupdate AT jhchristensen p1135subcutaneousepcoritamabincombinationwithritxuimablenalidomideinrelapsedorrefractoryfollicularlymphomaphase12trialupdate AT sdevos p1135subcutaneousepcoritamabincombinationwithritxuimablenalidomideinrelapsedorrefractoryfollicularlymphomaphase12trialupdate AT hholte p1135subcutaneousepcoritamabincombinationwithritxuimablenalidomideinrelapsedorrefractoryfollicularlymphomaphase12trialupdate AT kmlinton p1135subcutaneousepcoritamabincombinationwithritxuimablenalidomideinrelapsedorrefractoryfollicularlymphomaphase12trialupdate AT aabbas p1135subcutaneousepcoritamabincombinationwithritxuimablenalidomideinrelapsedorrefractoryfollicularlymphomaphase12trialupdate AT lwang p1135subcutaneousepcoritamabincombinationwithritxuimablenalidomideinrelapsedorrefractoryfollicularlymphomaphase12trialupdate AT mdinh p1135subcutaneousepcoritamabincombinationwithritxuimablenalidomideinrelapsedorrefractoryfollicularlymphomaphase12trialupdate AT belliott p1135subcutaneousepcoritamabincombinationwithritxuimablenalidomideinrelapsedorrefractoryfollicularlymphomaphase12trialupdate AT lfalchi p1135subcutaneousepcoritamabincombinationwithritxuimablenalidomideinrelapsedorrefractoryfollicularlymphomaphase12trialupdate |